CY1119356T1 - Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης - Google Patents

Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης

Info

Publication number
CY1119356T1
CY1119356T1 CY20171100458T CY171100458T CY1119356T1 CY 1119356 T1 CY1119356 T1 CY 1119356T1 CY 20171100458 T CY20171100458 T CY 20171100458T CY 171100458 T CY171100458 T CY 171100458T CY 1119356 T1 CY1119356 T1 CY 1119356T1
Authority
CY
Cyprus
Prior art keywords
pyridinyl
producers
synthesis
triazolone
malignancies
Prior art date
Application number
CY20171100458T
Other languages
English (en)
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1119356T1 publication Critical patent/CY1119356T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Αποκαλύπτονται ενώσεις του τύπου 1, ή φαρμακευτικώς αποδεκτά άλατα αυτών, όπου τα R1, R2, R3, και R4 ορίζονται στην προδιαγραφή. Αυτή η αποκάλυψη αφορά επίσης υλικά και μεθόδους για την παρασκευή ενώσεων του τύπου 1, φαρμακευτικές συνθέσεις οι οποίες τα περιέχουν, και τη χρήση αυτών για τη θεραπευτική αγωγή αντιδράσεων υπερευαισθησίας Τύπου I, αυτοάνοσων ασθενειών, φλεγμονωδών διαταραχών, καρκίνου, μη κακοηθών πολλαπλασιαστικών διαταραχών, και άλλων καταστάσεων που συνδέονται με ΒΤΚ.
CY20171100458T 2013-03-11 2017-04-25 Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης CY1119356T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (en) 2013-03-11 2014-03-10 Pyridinyl and fused pyridinyl triazolone derivatives

Publications (1)

Publication Number Publication Date
CY1119356T1 true CY1119356T1 (el) 2018-02-14

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100458T CY1119356T1 (el) 2013-03-11 2017-04-25 Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης

Country Status (42)

Country Link
US (4) US9402841B2 (el)
EP (2) EP3235814B1 (el)
JP (2) JP6271700B2 (el)
KR (1) KR102300612B1 (el)
CN (1) CN105121427B (el)
AP (1) AP2015008646A0 (el)
AR (1) AR095198A1 (el)
AU (1) AU2014249248B2 (el)
BR (1) BR112015020264B1 (el)
CA (1) CA2899948C (el)
CL (1) CL2015002370A1 (el)
CR (1) CR20150470A (el)
CY (1) CY1119356T1 (el)
DK (1) DK2970202T3 (el)
DO (1) DOP2015000184A (el)
EA (1) EA028584B1 (el)
EC (1) ECSP15042779A (el)
ES (2) ES2624439T3 (el)
GE (1) GEP201706778B (el)
HK (2) HK1220183A1 (el)
HR (1) HRP20170622T1 (el)
HU (1) HUE032720T2 (el)
IL (1) IL240353B (el)
JO (1) JO3377B1 (el)
LT (1) LT2970202T (el)
MA (1) MA38391B1 (el)
ME (1) ME02693B (el)
MX (1) MX364527B (el)
MY (1) MY183927A (el)
PE (1) PE20151889A1 (el)
PH (1) PH12015502046B1 (el)
PL (1) PL2970202T3 (el)
PT (1) PT2970202T (el)
RS (1) RS55879B1 (el)
SG (1) SG11201506112QA (el)
SI (1) SI2970202T1 (el)
TN (1) TN2015000342A1 (el)
TW (1) TWI637950B (el)
UA (1) UA114944C2 (el)
UY (1) UY35376A (el)
WO (1) WO2014164558A1 (el)
ZA (1) ZA201505996B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266895B2 (en) 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
MX2016010754A (es) 2014-02-21 2017-03-03 Principia Biopharma Inc Sales y forma solida de un inhibidor btk.
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
PL3233103T3 (pl) * 2014-12-18 2021-04-19 Principia Biopharma Inc. Leczenie pęcherzycy
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6876704B2 (ja) * 2015-12-24 2021-05-26 武田薬品工業株式会社 共結晶、その製造方法、及び共結晶を含有する医薬
PL3402503T3 (pl) * 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
US20190105407A1 (en) * 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
BR112018077503A2 (pt) 2016-06-29 2019-04-09 Principia Biopharma Inc. formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3135943A1 (en) * 2019-04-02 2020-10-08 Yonsei University, University-Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE294797T1 (de) * 2000-09-15 2005-05-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
RU2008133161A (ru) 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
JP5441691B2 (ja) * 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
CN101472884A (zh) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
SI2242749T1 (sl) 2008-02-05 2013-07-31 F.Hoffmann-La Roche Ag Novi piridinoni in piridazinoni
EP2297142B1 (en) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
RU2507202C2 (ru) 2008-07-02 2014-02-20 Ф.Хоффманн-Ля Рош Аг Новые фенилпиразиноны в качестве ингибиторов киназы
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
KR101820645B1 (ko) 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
US9308585B2 (en) 2010-11-10 2016-04-12 Stc.Unm Aerosol reduction/expansion synthesis (A-RES) for zero valent metal particles
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
ECSP15042779A (es) 2017-08-31
MY183927A (en) 2021-03-17
EP3235814B1 (en) 2018-12-12
HUE032720T2 (en) 2017-10-30
MX364527B (es) 2019-04-30
PT2970202T (pt) 2017-05-03
TW201522328A (zh) 2015-06-16
PL2970202T3 (pl) 2017-08-31
ZA201505996B (en) 2016-11-30
US20160310483A1 (en) 2016-10-27
EA028584B1 (ru) 2017-12-29
US10307414B2 (en) 2019-06-04
PH12015502046A1 (en) 2016-01-18
DOP2015000184A (es) 2015-11-30
WO2014164558A1 (en) 2014-10-09
KR102300612B1 (ko) 2021-09-09
KR20150126687A (ko) 2015-11-12
AU2014249248B2 (en) 2017-08-17
JP6462842B2 (ja) 2019-01-30
BR112015020264B1 (pt) 2021-03-02
TN2015000342A1 (en) 2017-01-03
US9402841B2 (en) 2016-08-02
DK2970202T3 (en) 2017-05-08
AU2014249248A1 (en) 2015-08-20
HRP20170622T1 (hr) 2017-06-30
JP2016512515A (ja) 2016-04-28
GEP201706778B (en) 2017-11-27
JP6271700B2 (ja) 2018-01-31
PH12015502046B1 (en) 2016-01-18
AR095198A1 (es) 2015-09-30
US20180015083A1 (en) 2018-01-18
JO3377B1 (ar) 2019-03-13
RS55879B1 (sr) 2017-08-31
BR112015020264A2 (pt) 2017-07-18
TWI637950B (zh) 2018-10-11
SG11201506112QA (en) 2015-09-29
SI2970202T1 (sl) 2017-07-31
MX2015011533A (es) 2016-02-03
EA201591686A1 (ru) 2015-12-30
CR20150470A (es) 2016-01-11
NZ710852A (en) 2020-12-18
IL240353B (en) 2018-11-29
EP2970202B1 (en) 2017-02-01
AP2015008646A0 (en) 2015-08-31
US20190224190A1 (en) 2019-07-25
HK1220183A1 (zh) 2017-04-28
LT2970202T (lt) 2017-06-12
CA2899948A1 (en) 2014-10-09
UA114944C2 (uk) 2017-08-28
ES2624439T3 (es) 2017-07-14
UY35376A (es) 2014-10-31
CN105121427B (zh) 2018-04-10
JP2018076357A (ja) 2018-05-17
PE20151889A1 (es) 2015-12-26
IL240353A0 (en) 2015-09-24
EP3235814A1 (en) 2017-10-25
ES2714166T3 (es) 2019-05-27
US9801872B2 (en) 2017-10-31
CN105121427A (zh) 2015-12-02
US20140256734A1 (en) 2014-09-11
ME02693B (me) 2017-10-20
CL2015002370A1 (es) 2016-03-11
MA38391B1 (fr) 2018-09-28
CA2899948C (en) 2021-11-16
MA38391A1 (fr) 2018-01-31
HK1245256B (zh) 2019-09-27
EP2970202A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CY1119356T1 (el) Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
CY1120104T1 (el) Αναστολεις της syk
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
BR112018008714A2 (pt) inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
CY1116736T1 (el) Συντηγμενες ετεροαρωματικες πυρρολιδινονες ως αναστολεις syk
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1119084T1 (el) Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
PH12015500063B1 (en) Azaindole derivatives which act as pi3k inhibitors
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
CY1122231T1 (el) Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια